Evidence was organized thematically into pharmacokinetics and discontinuation timing, safety of GLP-1 RA exposure in pregnancy, alternative metabolic management strategies, and ethical/clinical considerations
Efficacy and Safety of a Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Compared With its Components Given Alone: Results of a Phase 3, Open-Label, Randomised, 26-Week, Treat-to-Target Trial in Insulin-Naive Patients With Type 2 Diabetes
Most blood-in-stool claims fail for one of three reasons: Vague Symptomology: Using a general code when a specific one was available
Current guidance from the American Optometric Association outlines potential risks associated with GLP-1 therapies, including diabetic retinopathy progression and rare optic nerve complications, and emphasized the need for baseline exams and ongoing monitoring
Sereda M, Adjamian P, Edmondson-Jones M, Palmer AR, Hall DA
This combination logic is particularly relevant in therapy-resistant states where ferroptosis defense is upregulated